WO2010048149A3 - Heterocyclic modulators of gpr119 for treatment of disease - Google Patents

Heterocyclic modulators of gpr119 for treatment of disease Download PDF

Info

Publication number
WO2010048149A3
WO2010048149A3 PCT/US2009/061281 US2009061281W WO2010048149A3 WO 2010048149 A3 WO2010048149 A3 WO 2010048149A3 US 2009061281 W US2009061281 W US 2009061281W WO 2010048149 A3 WO2010048149 A3 WO 2010048149A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
gpr119
disease
heterocyclic modulators
modulators
Prior art date
Application number
PCT/US2009/061281
Other languages
French (fr)
Other versions
WO2010048149A2 (en
Inventor
Nicholas D. Smith
Celine Bonnefous
Mehmet Kahraman
Stewart A. Noble
Joseph E. Payne
Steven P. Govek
Original Assignee
Kalypsys, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10663808P priority Critical
Priority to US61/106,638 priority
Priority to US14385409P priority
Priority to US61/143,854 priority
Priority to US61/154,115 priority
Priority to US15411509P priority
Application filed by Kalypsys, Inc. filed Critical Kalypsys, Inc.
Publication of WO2010048149A2 publication Critical patent/WO2010048149A2/en
Publication of WO2010048149A3 publication Critical patent/WO2010048149A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Disclosed herein are compounds and methods which may be useful as inhibitors of GPR 119 for the treatment or prevention of diseases including cardiovascular and metabolic diseases.
PCT/US2009/061281 2008-10-20 2009-10-20 Heterocyclic modulators of gpr119 for treatment of disease WO2010048149A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10663808P true 2008-10-20 2008-10-20
US61/106,638 2008-10-20
US14385409P true 2009-01-12 2009-01-12
US61/143,854 2009-01-12
US15411509P true 2009-02-20 2009-02-20
US61/154,115 2009-02-20

Publications (2)

Publication Number Publication Date
WO2010048149A2 WO2010048149A2 (en) 2010-04-29
WO2010048149A3 true WO2010048149A3 (en) 2010-09-02

Family

ID=42119931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/061281 WO2010048149A2 (en) 2008-10-20 2009-10-20 Heterocyclic modulators of gpr119 for treatment of disease

Country Status (1)

Country Link
WO (1) WO2010048149A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940748B2 (en) 2009-10-08 2015-01-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009143389A1 (en) 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP2303859A4 (en) * 2008-06-20 2012-08-22 Metabolex Inc Aryl gpr119 agonists and uses thereof
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
EP2445901A1 (en) 2009-06-24 2012-05-02 Boehringer Ingelheim International GmbH New compounds, pharmaceutical composition and methods relating thereto
AR077215A1 (en) 2009-06-24 2011-08-10 Boehringer Ingelheim Int Piperidine derivatives, pharmaceutical compositions and methods related thereto
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
EP2493889B1 (en) 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
AR080754A1 (en) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Imidazo (1,2-a) pyrazine and their use as inhibitors of PDE10
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
BR112012027056A2 (en) 2010-04-22 2017-08-08 Vertex Pharma production process of cycloalkicarboxamidoindole compounds.
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
EP2585048B1 (en) 2010-06-23 2018-04-11 CymaBay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US8653092B2 (en) 2010-07-06 2014-02-18 Novartis Ag Tetrahydro-pyrido-pyrimidine derivatives
WO2012006955A1 (en) * 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. Compounds for treatment of metabolic disorders
AU2011311183B2 (en) 2010-10-08 2014-09-25 Cadila Healthcare Limited Novel GPR 119 agonists
SI2646444T1 (en) 2010-12-03 2016-09-30 Epizyme, Inc. Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes
CA2819625A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AR091739A1 (en) 2012-07-11 2015-02-25 Elcelyx Therapeutics Inc Compositions and methods for reducing cardiometabolic risk
US20120184572A1 (en) * 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
US8822471B2 (en) * 2011-03-14 2014-09-02 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
SG193982A1 (en) 2011-03-28 2013-11-29 Mei Pharma Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
MX360404B (en) 2011-05-04 2018-10-31 Ariad Pharma Inc Compounds for inhibiting cell proliferation in egfr-driven cancers.
EA201690655A1 (en) 2011-05-04 2017-01-30 Ризен Фармасьютикалз Са New connections as proteinkinase modulators
AR087701A1 (en) 2011-08-31 2014-04-09 Japan Tobacco Inc Pyrazole derivatives with inhibitory activity of SGLT1
IN2012CH01573A (en) 2012-04-20 2015-07-10 Advinus Therapeutics Ltd
CA2871471A1 (en) 2012-04-24 2013-10-31 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
JP6469567B2 (en) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Compound for inhibiting cell proliferation of EGFR-activated cancer
NZ630488A (en) 2012-06-12 2016-07-29 Chong Kun Dang Pharm Corp Piperidine derivatives for gpr119 agonist
JP6426603B2 (en) 2012-06-26 2018-11-21 ヤンセン ファーマシューティカ エヌ.ベー. A PDE2 inhibitor such as a 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] -quinoxaline compound and a PDE10 inhibitor for use in the treatment of a neurological or metabolic disorder combination
BR112015000459A2 (en) 2012-07-09 2017-06-27 Janssen Pharmaceutica Nv phosphodiesterase enzyme inhibitors 10
US20150284422A1 (en) 2012-08-10 2015-10-08 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
AR092924A1 (en) 2012-10-09 2015-05-06 Sanofi Sa Pyrrolidinone derivatives as modulators of GPR119 for the treatment of diabetes, obesity, dyslipidemia and related disorders
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9359380B2 (en) 2013-03-12 2016-06-07 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014239520A1 (en) 2013-03-15 2015-09-10 Epizyme, Inc. Methods of synthesizing substituted purine compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
KR101720937B1 (en) * 2013-04-25 2017-03-29 주식회사유한양행 Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same
DE102013008118A1 (en) 2013-05-11 2014-11-13 Merck Patent Gmbh arylchinazoline
AU2014299457B2 (en) * 2013-06-27 2017-06-08 Lg Chem, Ltd. Biaryl derivatives as GPR120 agonists
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
MD4635B1 (en) 2013-10-14 2019-06-30 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
RU2671496C2 (en) 2013-10-14 2018-11-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. 5-piperidin-8-cyanochinoline derivatives
RU2675270C2 (en) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Co-crystals and pharmaceutical compositions containing same
NZ720304A (en) 2013-11-26 2017-08-25 Chong Kun Dang Pharmaceutical Corp Amide derivatives for gpr119 agonist
SG10201808102WA (en) 2013-12-20 2018-10-30 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
JP2017501234A (en) * 2014-01-06 2017-01-12 ライゼン・ファーマシューティカルズ・エスアー New inhibitors of glutaminase
JP6473457B2 (en) 2014-01-17 2019-02-20 ノバルティス アーゲー 1- (Triazin-3-yl / pyridazin-3-yl) -piperidine / piperazine derivatives and compositions thereof for inhibiting the activity of SHP2
AU2015207757B8 (en) 2014-01-17 2017-05-11 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
JP6523303B2 (en) 2014-01-17 2019-05-29 ノバルティス アーゲー 1-Pyridazin / triazin-3-yl-piperazine / piperidine / pyrrolidine derivatives for inhibiting the activity of SHP2 and compositions thereof
PE20161573A1 (en) 2014-02-13 2017-01-19 Incyte Corp Cyclopropylamine as LSD1 inhibitor
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
AU2015217119B2 (en) 2014-02-13 2019-07-11 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
AR099936A1 (en) 2014-04-04 2016-08-31 Sanofi Sa Substituted fused heterocycles as modulators of GPR119 for treating diabetes, obesity, dyslipidemia and disorders related
TW201623286A (en) 2014-04-04 2016-07-01 賽諾菲公司 Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
CN106132949A (en) 2014-04-04 2016-11-16 赛诺菲 Substituted indone compound as the GPR119 regulator for the treatment of diabetes, obesity, dyslipidemia and associated conditions
EP3131582B1 (en) 2014-04-15 2018-05-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
BR112016025423A2 (en) 2014-05-01 2017-08-15 Novartis Ag compounds and compositions as toll-7 receptor agonists
EP3137468A1 (en) 2014-05-01 2017-03-08 Novartis AG Compounds and compositions as toll-like receptor 7 agonists
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag Compounds and compositions as kinase inhibitors
EA201790380A1 (en) 2014-09-17 2017-08-31 Селджен Кар Ллс Mk2 inhibitors and their applications
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
EA201792205A1 (en) 2015-04-03 2018-02-28 Инсайт Корпорейшн Heterocyclic compounds as lsd1 inhibitors
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
EP3310771A1 (en) 2015-06-19 2018-04-25 Novartis AG Compounds and compositions for inhibiting the activity of shp2
US10329255B2 (en) 2015-08-12 2019-06-25 Incyte Corporation Salts of an LSD1 inhibitor
CN109414410A (en) 2016-04-22 2019-03-01 因赛特公司 The preparation of LSD1 inhibitor
JP2019527693A (en) 2016-08-03 2019-10-03 サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
TW201838985A (en) 2017-01-23 2018-11-01 美商凱登製藥公司 Potassium channel modulators
AR110988A1 (en) 2017-02-21 2019-05-22 Sanofi Sa Azetidine compounds as modulators of GPR119 for treating diabetes, obesity, dyslipidemia, and related disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070562A1 (en) * 2003-07-11 2005-03-31 Jones Robert M. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20080058339A1 (en) * 2006-08-30 2008-03-06 Biovitrum New compounds
WO2008070692A2 (en) * 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070562A1 (en) * 2003-07-11 2005-03-31 Jones Robert M. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20080058339A1 (en) * 2006-08-30 2008-03-06 Biovitrum New compounds
WO2008070692A2 (en) * 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940748B2 (en) 2009-10-08 2015-01-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9428475B2 (en) 2009-10-08 2016-08-30 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use

Also Published As

Publication number Publication date
WO2010048149A2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
DK2796469T3 (en) New compositions and methods for the treatment of IgE-mediated disorders
DK1984357T3 (en) 2,4-pyrimidine diamine compounds for treatment or prevention of auto-immune diseases
DK1756084T3 (en) Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders related thereto
DK1934174T3 (en) Acetidines as MEK inhibitors for the treatment of proliferative diseases
DK2040713T3 (en) Bilic acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
EP2369017B8 (en) Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
EP1987141B8 (en) Compositions suitable for treating collagen-mediated diseases
IL257622D0 (en) Methods and compositions for the treatment of persistent infections
EP2063897A4 (en) Kinase inhibitors useful for the treatment of proliferative diseases
DE602006018583D1 (en) Method and composition for the treatment of peripheral vascular diseases
DE602007006815D1 (en) 4-a5-methoxy-6- (2-methyl-6-e1,2,4-utriazol-1-yl-pyridin-3-ylamino) -pyrimidine-4-yloxy-piperidin-1-carboxylic acid isopropyl ester as metabolic modulators and treatment of thus associated diseases
AT554747T (en) High viscosis of macromolecular compositions for the treatment of eye diseases
EP2107909A4 (en) Compounds and pharmaceutical compositions for the treatment of liver disorders
EP2146716A4 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
IL193900A (en) Pyrazoles for the treatment of metabolic disorders
HK1143929A1 (en) Composition and method for the prevention of oral disease
HK1183910A1 (en) Compositions and methods for inhibiting expression of the pcsk9 gene pcsk9
BRPI0921237A2 (en) methods and compositions for the treatment of complement-associated disorders
EP1871331A4 (en) Composition for treatment of menopause
AT418346T (en) Compositions for the treatment of neuropathic and neurodeegenerative diseases
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
EP2307025A4 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
IL187343D0 (en) Compositions and methods for the diagnosis and treatment of tumor
EP2073811A4 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
RU2007133098A (en) Composition for prevention of plant diseases and method for preventing diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09822536

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 09822536

Country of ref document: EP

Kind code of ref document: A2